You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Claims for Patent: 11,833,130

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,833,130

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US17/206,811
Patent Claims:	1. A method for the chronic treatment of Non-24 in a person who is totally blind comprising orally administering to the person a dose of tasimelteon in an amount of 20 to 50 mg once daily about one-half hour to about one-and-one-half hours before the person's desired bedtime. 2. The method of claim 1, wherein the dose of tasimelteon is 20 mg. 3. The method of claim 1, wherein the dose of tasimelteon is 50 mg. 4. The method of claim 1, wherein the tasimelteon is administered about one hour before the desired bedtime. 5. A method of advancing a person's circadian rhythm comprising orally administering the person a dose of tasimelteon in an amount of 20 mg to 50 mg once daily about one-half hour to about one-and-one-half hours before the person's desired bedtime. 6. The method of claim 5, wherein the dose of tasimelteon is 20 mg. 7. The method of claim 5, wherein the dose of tasimelteon is 50 mg. 8. The method of claim 5, wherein the tasimelteon is administered about one hour before the desired bedtime. 9. The method of claim 5, wherein the dose of tasimelteon advances the person's circadian rhythm up to about five hours. 10. A method of treating a patient suffering from Non-24 comprising: orally administering to said patient 20 mg of tasimelteon once daily before a target bedtime each day, for a dosing period sufficient to produce an improvement in said patient's Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST) and Upper Quartile of Days of Daytime Total Sleep Time (UQ-dTSD), wherein the improvement comprises an LQ-nTST increase of at least 45 minutes and a UQ-dTSD decrease of at least 45 minutes, relative to said patient's pretreatment LQ-nTST and UQ-dTSD.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.